Literature DB >> 17940246

Epilepsy in patients with pervasive developmental disorder not otherwise specified.

Antonia Parmeggiani1, Annio Posar, Chiara Antolini, Maria Cristina Scaduto, Margherita Santucci, Paola Giovanardi-Rossi.   

Abstract

Data on epilepsy in pervasive developmental disorder not otherwise specified are few and scanty. Seventy-seven patients with pervasive developmental disorder not otherwise specified were compared with 77 with autistic disorder, matched for age and sex. The 2 groups were divided into 3 subgroups each: A, without electroencephalography (EEG) paroxysmal abnormalities or epilepsy; B, with EEG paroxysmal abnormalities without epilepsy; and C, with epilepsy. Mild mental retardation (P < .01), pathological neurological examination (P < .05), cerebral lesions (P < .01), abnormal EEG background activity (P < .001), and associated genetic pathologies (P < .01) were more common in pervasive developmental disorder not otherwise specified. Familial antecedents for epilepsy prevailed in subgroup C (P < .01). Epilepsy occurred in 35.1% of patients with pervasive developmental disorder not otherwise specified, with no statistically significant difference compared with autistic disorder. The mean age of seizure onset was earlier (2 years 8 months) in pervasive developmental disorder not otherwise specified (P < .000). Seizure outcome was better in autistic disorder. Genetic diseases and cerebral lesions should be investigated in pervasive developmental disorder not otherwise specified to clarify the etiological and clinical features.

Entities:  

Mesh:

Year:  2007        PMID: 17940246     DOI: 10.1177/0883073807306265

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  9 in total

1.  The role of GABAergic system in neurodevelopmental disorders: a focus on autism and epilepsy.

Authors:  Paola Sgadò; Mark Dunleavy; Sacha Genovesi; Giovanni Provenzano; Yuri Bozzi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-09-09

2.  Epilepsy and other central nervous system diseases in atypical autism: a case control study.

Authors:  Svend Erik Mouridsen; Bente Rich; Torben Isager
Journal:  J Neural Transm (Vienna)       Date:  2011-01-05       Impact factor: 3.575

Review 3.  Epilepsy and Autism.

Authors:  Ashura W Buckley; Gregory L Holmes
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

Review 4.  What is more harmful, seizures or epileptic EEG abnormalities? Is there any clinical data?

Authors:  Gregory L Holmes
Journal:  Epileptic Disord       Date:  2014-10       Impact factor: 1.819

5.  Epilepsy among children and adolescents with autism spectrum disorders: a population-based study.

Authors:  Elina Jokiranta; Andre Sourander; Auli Suominen; Laura Timonen-Soivio; Alan S Brown; Matti Sillanpää
Journal:  J Autism Dev Disord       Date:  2014-10

Review 6.  The role of epilepsy and epileptiform EEGs in autism spectrum disorders.

Authors:  Sarah J Spence; Mark T Schneider
Journal:  Pediatr Res       Date:  2009-06       Impact factor: 3.756

7.  Temporal lobe connects regression and macrocephaly to autism spectrum disorders.

Authors:  Giulia Valvo; Sara Baldini; Alessandra Retico; Giuseppe Rossi; Raffaella Tancredi; Anna Rita Ferrari; Sara Calderoni; Fabio Apicella; Filippo Muratori; Filippo Maria Santorelli; Federico Sicca
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-07-30       Impact factor: 4.785

8.  Using quantitative and analytic EEG methods in the understanding of connectivity in autism spectrum disorders: a theory of mixed over- and under-connectivity.

Authors:  Robert Coben; Iman Mohammad-Rezazadeh; Rex L Cannon
Journal:  Front Hum Neurosci       Date:  2014-02-26       Impact factor: 3.169

9.  State-Dependent Differences in Functional Connectivity in Young Children With Autism Spectrum Disorder.

Authors:  Ashura W Buckley; Rod Scott; Anna Tyler; J Matthew Mahoney; Audrey Thurm; Cristan Farmer; Susan Swedo; Scott A Burroughs; Gregory L Holmes
Journal:  EBioMedicine       Date:  2015-11-05       Impact factor: 8.143

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.